Podcast Summary

Podcast: American Thought Leaders
Host: Jan Jekielek, The Epoch Times
Episode: Exclusive: Dr. Jay Bhattacharya on How the NIH Is Rethinking Autism, DEI, China Ties, and Gain-of-Function
Guest: Dr. Jay Bhattacharya, Director of the National Institutes of Health
Date: February 11, 2026

Episode Overview

This wide-ranging interview with Dr. Jay Bhattacharya, now Director of the NIH, delves into sweeping changes at the agency, critiques of DEI and politicization of biomedical research, international research partnerships (especially with China), gain-of-function research policy, the replication crisis in science, the controversy over vaccines and autism, and NIH’s renewed focus on tangible health outcomes. Throughout, Dr. Bhattacharya emphasizes a new vision for the NIH: prioritizing research that directly improves Americans' health over political, ideological, or bureaucratic measures of success.

Key Discussion Points & Insights

1. NIH’s Mission and Recent Reforms

Timestamps: 01:19–11:00

• Mission Clarified: NIH’s fundamental mandate is funding biomedical research to improve American health and longevity. It is not a public health policy or enforcement agency.
• Shift in Evaluation: Moving from quantity-focused metrics (e.g., number of publications) to outcome-driven goals—prioritizing research that can tangibly improve health.
• De-politicizing Science: Bhattacharya outlines efforts to remove ideological or political requirements—particularly DEI (diversity, equity, inclusion) mandates—citing an overreach in the past two decades:
  • “A chunk of the NIH portfolio went to projects that were focused on achieving some social objective rather than the health mission.” (03:30)
  • Now, only projects defined by rigorous science and demonstrable health benefit will be funded.

Quote:

“What we're not going to do is fund ideological projects. … If they want NIH support, they need to propose projects that will improve the health, that have the chance of improving health to people, rather than achieving some ideological end.” —Bhattacharya (07:54)

2. Overhaul of DEI and Political Agendas

Timestamps: 03:17–08:54

• DEI as 'Political Agenda': Dr. Bhattacharya criticizes how DEI projects were “loyalty oaths” rather than science.
• Example: Research with untestable hypotheses (e.g., “structural racism” as the root of health disparities) lacked actionable outcomes and scientific rigor.
• Change in Practice: Future funding decisions will be based solely on scientific merit and impact.

3. NIH’s Relationship with China and International Collaboration

Timestamps: 11:00–21:14

• Past Engagements: The U.S. (via NIH) invested heavily in China’s biomedical research, including training and funding leading Chinese scientists.
• Pandemic Reassessment: Collaborations with Chinese labs—particularly gain-of-function research—are now considered risky.
• Structural Change:
  • Subaward system replaced with a “subproject” system, requiring direct NIH auditing and data access for any institution, foreign or domestic.
  • If an institution (like those in China) cannot provide such transparency and auditing, NIH will not fund them: “If American taxpayer dollars are going to go to some foreign institution, then we should be confident that […] we have a auditing relationship.” (15:14)
• Ethical Standard: No collaboration with entities violating human rights or basic bioethics.

Quote:

“If it's not possible to have the criteria that I said earlier for research projects with the Chinese institutions, then we won't have those research projects.” —Bhattacharya (19:00)

4. Redefining Research Success & Funding Innovation

Timestamps: 22:36–30:44

• Beyond Publications: The value of research is no longer measured in papers published but in field-advancing ideas and actual cures.
• Risk Taking Encouraged: Institutes are now expected to take intellectual risks and fund more innovative (potentially ‘failing’) projects if they have the chance at major breakthroughs.
  • “If you fund 50 projects and 49 of them fail, and the 50th cures type 2 diabetes, that’s a successful portfolio.” (24:30 & 25:54)
• Peer Review Changes: Elimination of rigid ‘pay lines’ that favored safe, non-innovative projects. Institutes are evaluated based on their portfolios’ collective success in advancing human health.

5. Policy on Gain-of-Function Research

Timestamps: 30:44–46:11

• Dangerous vs. Benign Gain-of-Function:
  • Benign examples: Engineering bacteria to produce insulin.
  • Dangerous: Manipulating viruses (e.g., coronaviruses from bats) to be more transmissible among humans.
• Policy: All dangerous gain-of-function research is paused; NIH will only fund such work if it survives rigorous, independent risk assessment, akin to nuclear regulatory frameworks.
  • New requirements include institution- and investigator-level risk evaluation and a third-party board’s oversight.
• Transparency: Past regulatory boards rarely reviewed such projects; that is changing under new federal policies.

Quote:

“We want to make it so that there's never any support or interest in doing that kind of dangerous work ever again.” —Bhattacharya (32:23)
“If a researcher says, ‘I'm going to go to the bat caves of China and pull out a virus and then make it more transmissible,’ then they are going to be responsible for doing a calculation—what’s the probability of it causing a worldwide pandemic?” (43:01)

6. The Replication Crisis & Democratizing Science

Timestamps: 51:17–59:54

• Replication Problem: Many high-profile biomedical research findings cannot be replicated.
• Root Issues: Publication in top journals is treated as ‘truth’ rather than successful replication.
• Planned Reforms:
  • Fund and support replication studies and reproducibility work.
  • Launch a public platform for publishing replication studies (even those contradicting original findings). User-friendly features (like a “replication button”) planned to increase transparency.
  • Reward open data/code-sharing and collaborative rather than adversarial scientific behavior.
• Vision: Move “truth-determination” power from elite journal editors to the broader scientific community.

Quote:

“The situation today is analogous [to pre-scientific revolution]. … You have the power to determine truth being decided by a relatively small number of powerful journal editors…” (54:27)
“The NIH has the capacity to induce that second scientific revolution…” (54:44)

7. Changing Funding Patterns and Institutional Competition

Timestamps: 59:54–69:10

• No Overall Funding Cuts: Budgets remain strong, but grants are shifting to innovative projects, early-career researchers, and non-elite institutions.
• Facility Support Problem: Historic bias toward elite institutions (due to indirect cost linkage) entrenched power. Bhattacharya aims to introduce market competition for facility support and democratize NIH-funded research centers nationwide.
  • Young scientists often can’t get lab space at elite centers; changing this would accelerate broader scientific progress.

8. Industry Influence, Conflicts of Interest & Transparency

Timestamps: 69:10–72:09

• Financial Incentives: Concerns about pharmaceutical funding, conflicts of interest, and royalty streams influencing research priorities.
• NIH Response: Developing platforms for full transparency—like public databases of financial ties for scientists, modeled after databases for physicians.

9. Vaccines, Gene Therapies, and Surveillance

Timestamps: 72:09–76:41

• NIH Role: Clarifies NIH funds research but doesn’t approve, recommend, or monitor vaccine products (that’s FDA/CDC).
• COVID Vaccine Injuries: NIH increasingly funds research into vaccine injury, long COVID, chronic Lyme, ME/CFS.
  • “I've made sure that people know at the NIH that I'm very interested in investing in answers for patients for all of those...We need to get better answers.” (74:42)

10. Autism Controversy

Timestamps: 77:45–86:58

• Autism Etiology: “I don’t know the answer,” says Bhattacharya; the rise in prevalence has many hypotheses—genetic, environmental, etc.
• Vaccines and Autism:
  • On MMR, considers the “high-quality studies” showing no link “honest attempts”; recognizes people may disagree with existing research and supports more studies.
  • On vaccine schedules/combinations: Admits it’s a scientifically “very difficult” and under-researched problem.
  • Encourages open research agenda, no longer treating the topic as taboo.

Quote:

“It’s become a taboo thing to do, but it really should just be a research agenda.” (29:38, reprised at 81:17 & 86:58)

11. Vaccine Mandates and Public Health Trust

Timestamps: 82:41–86:58

• Mandates Not the Solution: Bhattacharya favors European-style shared decision-making over coercion — “most European countries do not have mandates even for measles,” yet have high uptake due to public trust.
• Lessons from COVID: American public health must regain trust through transparency, honesty, and treating public concerns with respect.

Quote:

“American public health essentially has earned distrust. … The job of the NIH is to fund research so that we get answers for people to the questions that they have. Even if some people think that the question’s already settled, … the right respectful thing to do is … to provide more better scientific answers…” (86:58)

Notable/Memorable Quotes

• (03:30) “Every single NIH employee had to write some, I can only call it a loyalty oath to DEI principles.” —Bhattacharya
• (15:14) “If American taxpayer dollars are going to go to some foreign institution, then we should be confident that we … have an auditing relationship.”
• (24:30 & 25:54) “If you fund 50 projects and 49 of them fail, and the 50th cures type 2 diabetes, that’s a successful portfolio. If every single project succeeds and all you get is a thousand papers published, I don’t care.”
• (32:23) “We want to make it so that there's never any support or interest in doing that kind of dangerous work ever again.”
• (54:44) “The NIH has the capacity to induce that second scientific revolution … [to] fundamentally transform science.”
• (81:17) “Do vaccines cause autism is a poorly formed question. … These are things that are worthy of research and something actually like, generally it's not like it's become a taboo thing to do, but it really should just be a research agenda.”
• (86:58) “The job of the NIH is to fund research so that we get answers for people to the questions that they have.”

Memorable Moments

• [00:51] Bhattacharya dismantles the idea of “success” as all projects succeeding; it’s about “swinging for the fences.”
• [15:54] Description of EcoHealth Alliance’s sub-awarding to Wuhan, and how this led to NIH losing oversight—prompting a structural overhaul.
• [48:10] Discussion of the Proximal Origins paper, and its role in shutting down lab leak debate: “People who were legitimately concerned ... got smeared, marginalized, censored …”
• [54:18] Bhattacharya likens the current state of science to pre-Galilean epistemology, calling for a “second scientific revolution” led by broader replication efforts.
• [79:11–82:41] Extended, nuanced discussion about autism’s causes, the scientific challenges in investigating vaccines and autism, with calls for honest inquiry (not censorship or mandates).

Key Segment Timestamps

• 01:19 — Major changes at NIH, new focus on outcomes.
• 03:17 — Politicization of science and DEI discussion.
• 11:29 — US-China research relationships, post-pandemic security changes.
• 22:56 — Research outcomes vs. paper count; risk and innovation.
• 30:44 — Gain-of-function, new regulatory philosophy.
• 51:17 — The replication crisis, the need for “democratization” of science.
• 59:54 — Funding patterns, institutional competition, early-career scientists.
• 69:10 — Industry influence and plans for transparency.
• 72:09 — NIH role in vaccine surveillance, focus on vaccine injury research.
• 77:45 — Autism, vaccine questions, scientific humility.
• 82:41 — Mandates, trust, transparency, and public health.

Conclusion

Dr. Jay Bhattacharya portrays an NIH evolving toward scientific rigor, outcome orientation, risk-taking, transparency, and public responsiveness. Ideological projects and bureaucratic inertia are out; open scientific inquiry and impact are in. Controversial questions are to be researched, not suppressed—even when they're uncomfortable or politically fraught. And major reforms, from gain-of-function oversight to grant distribution and scientific replication, are underway.

Tone: Forthright, sometimes critical of the past, but ultimately optimistic and committed to scientific progress in service of the public good.